

PI Major Mutations:None

PI Accessory Mutations:None

PR Other Mutations:[T12K](#) • [I13R](#) • K14R • [I15G](#) • G16E • G17R • [Q18G](#) • [L19G](#) • [K20G](#) • E21K • [A22G](#) • [L23R](#) • [L24V](#) • [D25A](#) • [T26D](#) • [G27K](#) • [A28R](#) • [D29R](#) • [D30R](#) • [T31E](#) • [V32K](#) • M36I • R41K • K43R • I62V • L63Q • I64V • E65D

Protease Inhibitors	
atazanavir/r (ATV/r)	Susceptible
darunavir/r (DRV/r)	Susceptible
fosamprenavir/r (FPV/r)	Susceptible
indinavir/r (IDV/r)	Susceptible
lopinavir/r (LPV/r)	Susceptible
nelfinavir (NFV)	Susceptible
saquinavir/r (SQV/r)	Susceptible
tipranavir/r (TPV/r)	Susceptible

- PR comments
- Other
- L24I is a non-polymorphic mutation selected by IDV and LPV. It contributes reduced susceptibility to ATV and LPV. L24F/M are uncommon non-polymorphic PI-selected mutations. L24F has a susceptibility profile similar to L24L. **L24V** is a highly unusual mutation at this position.
  - D30N is a non-polymorphic mutation NFV-selected mutation that causes high-level resistance to NFV but not to other PIs. **D30R** is a highly unusual mutation at this position.
  - V32I is a non-polymorphic mutation selected by LPV, ATV, and DRV which is associated with reduced susceptibility to each of these PIs. **V32K** is a highly unusual mutation at this position.

No drug resistance mutations were found for PI.

NRTI Mutations:[K70E](#) • [M184I](#) • [K219R](#)

NNRTI Mutations:[K103N](#) • [Y181C](#) • [G190A](#) • [H221Y](#)

RT Other Mutations:I31V • V35T • K49R • V60I • V90I • D121Y • K122E • D123E • S163T • T165I • D177E • I178M • [T200X](#) • E203K • [E204\\*](#) • Q207E • R211K • [F214X](#) • [K223X](#) • L228R • [D237X](#) • I244V • [V245X](#) • [P247H](#) • E248D • [N263M](#) • [W266G](#) • [A267Q](#) • [S268A](#) • [Q269I](#)

Nucleoside Reverse Transcriptase Inhibitors		Non-nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Intermediate Resistance	doravirine (DOR)	Intermediate Resistance
zidovudine (AZT)	Susceptible	efavirenz (EFV)	High-Level Resistance
stavudine (D4T)	Low-Level Resistance	etravirine (ETR)	High-Level Resistance
didanosine (DDI)	Intermediate Resistance	nevirapine (NVP)	High-Level Resistance
emtricitabine (FTC)	High-Level Resistance	rilpivirine (RPV)	High-Level Resistance
lamivudine (3TC)	High-Level Resistance		
tenofovir (TDF)	Low-Level Resistance		

- RT comments
- NRTI
- [K70E/Q/N/T/S/G](#) cause low-leve resistance to ABC and TDF.
  - [M184V/I](#) cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC (3-fold reduced susceptibility). [M184V/I](#) are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication.
  - [K219E/Q/N/R](#) are accessory TAMs that usually occur in combination with multiple other TAMs.
- NNRTI
- [K103N](#) is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM.
  - [Y181C](#) is a non-polymorphic mutation selected in persons receiving NVP, ETR and RPV. It confers high-level resistance to NVP, intermediate resistance to ETR and RPV, and low-level resistance to EFV. It does not significantly reduce DOR susceptibility.
  - [G190A](#) is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It does not significantly reduce susceptibility to RPV, ETR, or DOR.
  - [H221Y](#) is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C.
- Other
- [V90I](#) is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It is associated with minimal, if any, detectable reduction in NNRTI susceptibility.

Drug resistance mutation scores of NRTI:

Download CSV

Rule	ABC ⇅	AZT ⇅	D4T ⇅	DDI ⇅	FTC ⇅	3TC ⇅	TDF ⇅
<a href="#">K70E</a>	15	0	15	15	10	10	15
<a href="#">M184I</a>	15	-10	-10	10	60	60	-10
<a href="#">K219R</a>	5	10	10	5	0	0	5
<a href="#">K70E + M184I</a>	0	0	10	0	0	0	10
Total	35	0	25	30	70	70	20



Rule	DOR	EFV	ETR	NVP	RPV
<u>K103N + Y181C</u>	5	0	0	0	0
<u>Y181C</u>	10	30	30	60	45
<u>Y181C + G190A</u>	10	0	10	0	10
<u>Y181C + H221Y</u>	10	0	0	0	10
<u>H221Y</u>	10	10	10	15	15
<u>K103N</u>	0	60	0	60	0
<u>G190A</u>	0	45	10	60	15
Total	45	145	60	195	95